Shots:

• Taisho to acquire BMS’ UPSA Consumer Health Business for $1.6B- in all stock transaction with the put option. The transaction is expected to close in H1’19
• The focus of the agreement is to allow BMS to emphasize on its portfolio offering treatments in serious diseases and strengthen Taisho’s OTC platform
• UPSA develops and delivers medicines in multiple therapeutic areas like pain- cough & cold- gastrointestinal and sleep for patients in France- across EU and additional countries

Ref: Bristol Myers Squibb | Image: BMS